518 related articles for article (PubMed ID: 29249461)
21. Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.
Yenkoidiok-Douti L; Jewell CM
ACS Biomater Sci Eng; 2020 Feb; 6(2):759-778. PubMed ID: 33313391
[TBL] [Abstract][Full Text] [Related]
22. Harnessing the layer-by-layer assembly technique to design biomaterials vaccines for immune modulation in translational applications.
Tang T; Weng T; Jia H; Luo S; Xu Y; Li L; Zhang P
Biomater Sci; 2019 Feb; 7(3):715-732. PubMed ID: 30762040
[TBL] [Abstract][Full Text] [Related]
23. Letter from the editor.
Ellis R; Riedmann EM
Hum Vaccin Immunother; 2014; 10(4):813-4. PubMed ID: 24784356
[No Abstract] [Full Text] [Related]
24. 4th Australasian vaccines and immunotherapeutic development meeting.
Engwerda C; Belz G
Immunol Cell Biol; 2012 Nov; 90(10):921-4. PubMed ID: 23190698
[TBL] [Abstract][Full Text] [Related]
25. MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases.
Xu M; Li J; Gulfo JV; Von Hofe E; Humphreys RE
Scand J Immunol; 2001; 54(1-2):39-44. PubMed ID: 11439146
[TBL] [Abstract][Full Text] [Related]
26. Delivery strategies of cancer immunotherapy: recent advances and future perspectives.
Zhao Z; Zheng L; Chen W; Weng W; Song J; Ji J
J Hematol Oncol; 2019 Nov; 12(1):126. PubMed ID: 31779642
[TBL] [Abstract][Full Text] [Related]
27. 24th "Nantes Actualités en Transplantation" and 4th "LabEx Immunotherapy-Graft-Oncology" NAT and IGO Joint Meeting "New Horizons in Immunotherapy".
Joalland N; Ducoin K; Cadiou G; Rabu C; Guillonneau C
Front Immunol; 2021; 12():738312. PubMed ID: 34539674
[TBL] [Abstract][Full Text] [Related]
28. How immunoglobulin G antibodies kill target cells: revisiting an old paradigm.
Biburger M; Lux A; Nimmerjahn F
Adv Immunol; 2014; 124():67-94. PubMed ID: 25175773
[TBL] [Abstract][Full Text] [Related]
29. Report about the XVIIIth meeting of the Cancer Research Institute in its international cancer immunotherapy symposium series on October 6-8, 2010.
Hockertz S
Toxicology; 2011 Jan; 279(1-3):203-7. PubMed ID: 21204306
[No Abstract] [Full Text] [Related]
30. Harnessing Biomaterials to Study and Direct Antigen-Specific Immunotherapy.
Edwards C; Carey ST; Jewell CM
ACS Appl Bio Mater; 2023 Jun; 6(6):2017-2028. PubMed ID: 37068126
[TBL] [Abstract][Full Text] [Related]
31. Advances in cellular therapy: 6th International Symposium on the clinical use of cellular products, March 24 and 25, 2011, Erlangen, Germany.
Ullrich E; Bosch J; Aigner M; Voelkl S; Kroeger I; Hoffmann P; Kreutz M; Dudziak D; Gerbitz A
Cancer Immunol Immunother; 2012 Mar; 61(3):433-43. PubMed ID: 22200930
[No Abstract] [Full Text] [Related]
32. Improving the clinical impact of biomaterials in cancer immunotherapy.
Gammon JM; Dold NM; Jewell CM
Oncotarget; 2016 Mar; 7(13):15421-43. PubMed ID: 26871948
[TBL] [Abstract][Full Text] [Related]
33. New Insights for Immune-Based Diagnosis and Therapy for Infectious Diseases.
Sautto GA; Diotti RA; Wisskirchen K; Kahle KM
J Immunol Res; 2017; 2017():3104719. PubMed ID: 28758132
[No Abstract] [Full Text] [Related]
34. Systems biology applied to vaccine and immunotherapy development.
Buonaguro L; Wang E; Tornesello ML; Buonaguro FM; Marincola FM
BMC Syst Biol; 2011 Sep; 5():146. PubMed ID: 21933421
[TBL] [Abstract][Full Text] [Related]
35. Next-generation regulatory T cell therapy.
Ferreira LMR; Muller YD; Bluestone JA; Tang Q
Nat Rev Drug Discov; 2019 Oct; 18(10):749-769. PubMed ID: 31541224
[TBL] [Abstract][Full Text] [Related]
36. The emerging therapeutic role of antibody mixtures.
Robak T
Expert Opin Biol Ther; 2013 Jul; 13(7):953-8. PubMed ID: 23646883
[TBL] [Abstract][Full Text] [Related]
37. Biomaterials for vaccine-based cancer immunotherapy.
Zhang R; Billingsley MM; Mitchell MJ
J Control Release; 2018 Dec; 292():256-276. PubMed ID: 30312721
[TBL] [Abstract][Full Text] [Related]
38. Present Yourself! By MHC Class I and MHC Class II Molecules.
Rock KL; Reits E; Neefjes J
Trends Immunol; 2016 Nov; 37(11):724-737. PubMed ID: 27614798
[TBL] [Abstract][Full Text] [Related]
39. Harnessing biomaterials to engineer the lymph node microenvironment for immunity or tolerance.
Andorko JI; Hess KL; Jewell CM
AAPS J; 2015 Mar; 17(2):323-38. PubMed ID: 25533221
[TBL] [Abstract][Full Text] [Related]
40. DNA vaccines: an historical perspective and view to the future.
Liu MA
Immunol Rev; 2011 Jan; 239(1):62-84. PubMed ID: 21198665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
